Saccharomyces boulardii
Saccharomyces boulardii is a probiotic yeast studied for diarrhea and gut-related outcomes.
Overview
What is Saccharomyces boulardii?
Saccharomyces boulardii is a probiotic yeast isolated from lychee and mangosteen skins.
Dosage
A typical dose of S. boulardii is 500–1,000 mg per day (10–20 billion CFU).
Effect graph
Effect heatmap
SupplementDEX Database
23 conditions for , and rated at least stars. All purchase bands. No minimum star filter.
Database Snapshot
Most saccharomyces boulardii research is concentrated in a handful of conditions.
- Antibiotic-associated diarrhea accounts for 16 of 85 studies (19%).
- Diarrhea accounts for 15 of 85 studies (18%).
- C. difficile infection accounts for 13 of 85 studies (15%).
- Sparse coverage remains for Heart failure, Neonatal jaundice, Small intestinal bacterial overgrowth (SIBO).
Dietary Sources
Top dietary sources
Food sources
Sources include Is Present on the Peels of Lychee, Kefir, and Kombucha.
Safety
Oral S. boulardii is likely safe when used in typical doses.
Frequently Asked Questions
References
Sources82 references
SupplementDEX uses only high-quality sources to determine supplement effectiveness.
1.SupplementDEX Database: Antibiotic-associated diarrhea — Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis2017
A meta-analysis of 17 RCTs found probiotics reduced outpatient antibiotic-associated diarrhea incidence versus placebo (RR 0.54).
2.SupplementDEX Database: Antibiotic-associated diarrhea — Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial2016
In 368 hospitalized adults, Saccharomyces boulardii did not significantly prevent antibiotic-associated or C. difficile diarrhea versus placebo.
3.SupplementDEX Database: Antibiotic-associated diarrhea — Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea2015
A meta-analysis found S. boulardii reduced antibiotic-associated diarrhea risk versus control in adults and children.
4.SupplementDEX Database: Antibiotic-associated diarrhea — Probiotics for the prevention of pediatric antibiotic-associated diarrhea2015
A meta-analysis found probiotics reduced pediatric antibiotic-associated diarrhea, with S. boulardii among effective strains.
5.SupplementDEX Database: Antibiotic-associated diarrhea — Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial2012
In hospitalized antibiotic recipients, S. boulardii reduced antibiotic-associated diarrhea versus placebo.
6.SupplementDEX Database: Antibiotic-associated diarrhea — Meta-analysis: probiotics in antibiotic-associated diarrhoea2012
A meta-analysis found probiotics reduced antibiotic-associated diarrhea odds by about 42% versus placebo.
7.SupplementDEX Database: Antibiotic-associated diarrhea — Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis2012
A 2012 systematic review found probiotics, including S. boulardii, reduced antibiotic-associated diarrhea versus placebo.
8.SupplementDEX Database: Antibiotic-associated diarrhea — Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease2006
A meta-analysis found probiotics reduced antibiotic-associated diarrhea and may reduce C. difficile disease risk.
9.SupplementDEX Database: Antibiotic-associated diarrhea — Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study2006
In military patients, prophylactic S. boulardii reduced antibiotic-associated diarrhea versus placebo during antibiotic courses.
10.SupplementDEX Database: Antibiotic-associated diarrhea — Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea2005
A meta-analysis confirmed S. boulardii prevents antibiotic-associated diarrhea in children and adults versus placebo.
11.SupplementDEX Database: Antibiotic-associated diarrhea — Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial2005
In 269 children on antibiotics, S. boulardii 250 mg twice daily reduced diarrhea versus placebo.
12.SupplementDEX Database: Antibiotic-associated diarrhea — The probiotic effect of Saccharomyces boulardii in a pediatric age group2004
In 466 children on antibiotics, S. boulardii reduced antibiotic-associated diarrhea, especially when baseline sleep latency was long.
13.SupplementDEX Database: Antibiotic-associated diarrhea — Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis2002
A meta-analysis of 9 trials found S. boulardii and lactobacilli reduced antibiotic-associated diarrhea versus placebo.
14.SupplementDEX Database: Antibiotic-associated diarrhea — The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients1998
In elderly inpatients on antibiotics, S. boulardii did not significantly prevent antibiotic-associated diarrhea versus placebo.
15.SupplementDEX Database: Antibiotic-associated diarrhea — Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo1995
In beta-lactam recipients, S. boulardii 1 g/day reduced antibiotic-associated diarrhea versus placebo.
16.SupplementDEX Database: Antibiotic-associated diarrhea — Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study1989
In 180 hospitalized patients, S. boulardii cut antibiotic-associated diarrhea to 9.5% versus 22% on placebo.
SupplementDEX Database · C. difficile infection
10 references17.SupplementDEX Database: C. difficile infection — Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)2018
Updated IDSA/SHEA C. difficile guidelines discuss probiotics cautiously; routine S. boulardii prophylaxis was not strongly recommended.
18.SupplementDEX Database: C. difficile infection — Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study2018
Hospital-wide S. boulardii prophylaxis did not significantly reduce C. difficile infection rates versus usual care in a prospective study.
19.SupplementDEX Database: C. difficile infection — Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis2016
A meta-analysis found probiotics reduced C. difficile-associated diarrhea in adults and children, including S. boulardii regimens.
20.SupplementDEX Database: C. difficile infection — Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection2015
Removing automatic S. boulardii prescribing was associated with higher hospital-onset C. difficile rates in a before-after study.
21.SupplementDEX Database: C. difficile infection — Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children2013
A meta-analysis found probiotics reduced C. difficile-associated diarrhea in adults versus placebo, though strain-specific effects varied.
22.SupplementDEX Database: C. difficile infection — Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis2012
A systematic review found probiotics reduced C. difficile-associated diarrhea versus placebo or no treatment in antibiotic recipients.
23.SupplementDEX Database: C. difficile infection — Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)2010
2010 IDSA guidelines for C. difficile infection updated diagnosis and treatment recommendations; probiotics were not first-line prevention.
24.SupplementDEX Database: C. difficile infection — The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii2000
In recurrent C. difficile patients, S. boulardii plus standard antibiotics reduced further recurrences versus antibiotics alone in high-risk patients.
25.SupplementDEX Database: C. difficile infection — A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease1994
In C. difficile-associated disease, S. boulardii plus vancomycin or metronidazole reduced recurrence versus antibiotics plus placebo.
26.SupplementDEX Database: C. difficile infection — Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii1989
In 13 patients with recurrent C. difficile colitis, S. boulardii during vancomycin treatment reduced further recurrences versus historical controls.
SupplementDEX Database · Diarrhea
15 references27.SupplementDEX Database: Diarrhea — Effectiveness and Safety of Saccharomyces Boulardii for the Treatment of Acute Gastroenteritis in the Pediatric Population: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2022
A meta-analysis found S. boulardii reduced acute gastroenteritis duration and stool frequency in children under 5 versus control.
28.SupplementDEX Database: Diarrhea — Which Probiotic Is the Most Effective for Treating Acute Diarrhea in Children? A Bayesian Network Meta-Analysis of Randomized Controlled Trials2021
A network meta-analysis found S. boulardii among the more effective probiotics for shortening acute diarrhea in children.
29.SupplementDEX Database: Diarrhea — Effect of Saccharomyces boulardii CNCM-I 3799 and Bacillus subtilis CU-1 on Acute Watery Diarrhea: A Randomized Double-Blind Placebo-Controlled Study in Indian Children2021
In 180 children with acute diarrhea, combined S. boulardii and B. subtilis with ORS and zinc improved recovery versus placebo.
30.SupplementDEX Database: Diarrhea — Comparison of safety, effectiveness and serum inflammatory factor indexes of Saccharomyces boulardii versus Bifidobacterium triple viable in treating children with chronic diarrhea: a randomized trial2021
In 161 children with chronic diarrhea, S. boulardii improved recovery rate and safety profile versus bifidobacterium triple viable.
31.SupplementDEX Database: Diarrhea — A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea2020
In 100 infants with acute diarrhea, S. boulardii CNCM I-3799 5 billion CFU twice daily improved recovery versus placebo over 5 days.
32.SupplementDEX Database: Diarrhea — Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update2020
A meta-analysis found S. boulardii shortened acute gastroenteritis in children versus no treatment or placebo.
33.SupplementDEX Database: Diarrhea — Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: A systematic review and network meta-analysis2018
A comparative effectiveness review found zinc, probiotics including S. boulardii, and some antidiarrheals shorten acute diarrhea in children.
34.SupplementDEX Database: Diarrhea — Clinical Efficacy Comparison of Saccharomyces Boulardii and Lactic Acid as Probiotics in Acute Pediatric Diarrhea2018
In children with acute diarrhea, S. boulardii and lactic acid probiotics both shortened illness versus usual care, with similar efficacy.
35.SupplementDEX Database: Diarrhea — Comparison of Two Forms of Loperamide-Simeticone and a Probiotic Yeast (Saccharomyces boulardii) in the Treatment of Acute Diarrhoea in Adults: A Randomised Non-Inferiority Clinical Trial2015
In adults with acute diarrhea, loperamide-simeticone and S. boulardii both improved symptoms versus placebo, with similar tolerability.
36.SupplementDEX Database: Diarrhea — Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea2015
In children with acute watery diarrhea, S. boulardii CNCM I-745 reduced duration of diarrhea and hospital stay versus standard care.
37.SupplementDEX Database: Diarrhea — Efficacy and safety of Saccharomyces boulardii for acute diarrhea2014
A systematic review found S. boulardii effective and safe for acute childhood diarrhea, though trial quality varied.
38.SupplementDEX Database: Diarrhea — Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial2012
In children aged 3 months to 5 years, S. boulardii 250 mg twice daily for 5 days shortened diarrhea duration versus placebo.
39.SupplementDEX Database: Diarrhea — Effects of Saccharomyces boulardii in children with acute diarrhoea2005
In 200 children with acute diarrhoea, S. boulardii 250 mg for 5 days reduced stool frequency faster than placebo after day 2.
40.SupplementDEX Database: Diarrhea — Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children2003
In 89 children with persistent diarrhea, Lactobacillus or S. boulardii shortened illness versus placebo.
41.SupplementDEX Database: Diarrhea — Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial1997
In tube-fed ICU patients, S. boulardii 500 mg four times daily did not significantly reduce diarrhea incidence versus placebo.
42.SupplementDEX Database: Helicobacter pylori (H. pylori) — Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis2025
A meta-analysis of 19 H. pylori trials (n=5036) found Saccharomyces boulardii adjuvant therapy raised eradication rate and reduced diarrhea and other adverse effects.
43.SupplementDEX Database: Helicobacter pylori (H. pylori) — The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study2023
In 172 H. pylori patients, adding S. boulardii to antofloxacin-bismuth quadruple therapy raised eradication and reduced adverse events versus quadruple therapy alone.
44.SupplementDEX Database: Helicobacter pylori (H. pylori) — The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials2023
A meta-analysis found S. boulardii added to standard triple therapy increased H. pylori eradication in children versus STT alone.
45.SupplementDEX Database: Helicobacter pylori (H. pylori) — Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial2022
In 156 H. pylori patients, quadruple therapy plus S. boulardii or L. reuteri improved eradication and reduced side effects versus quadruple therapy alone.
46.SupplementDEX Database: Helicobacter pylori (H. pylori) — Saccharomyces boulardii Allows Partial Patients to Avoid Reusing Bismuth Quadruple for Helicobacter pylori Rescue Therapy: A Single-Center Randomized Controlled Study2022
In 100 H. pylori patients, pretreatment with S. boulardii allowed some patients to avoid repeat bismuth quadruple rescue therapy.
47.SupplementDEX Database: Helicobacter pylori (H. pylori) — Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial2021
In 360 H. pylori patients, S. boulardii plus quadruple therapy improved eradication and reduced treatment side effects versus quadruple therapy alone.
48.SupplementDEX Database: Helicobacter pylori (H. pylori) — Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy2020
In H. pylori patients, S. boulardii or broccoli sprout supplementation did not significantly increase eradication versus standard triple therapy.
49.SupplementDEX Database: Helicobacter pylori (H. pylori) — Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis2019
A meta-analysis found S. boulardii as H. pylori adjuvant therapy increased eradication rates and reduced adverse effects versus antibiotics alone.
50.SupplementDEX Database: Helicobacter pylori (H. pylori) — Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial2019
In H. pylori patients, sequential therapy plus S. boulardii CNCM I-745 improved eradication and lowered adverse events versus sequential therapy alone.
51.SupplementDEX Database: Helicobacter pylori (H. pylori) — Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection2015
A meta-analysis found S. boulardii adjuvant therapy increased H. pylori eradication and reduced therapy-associated side effects versus control.
52.SupplementDEX Database: Helicobacter pylori (H. pylori) — Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication2005
In peptic ulcer patients on 14-day H. pylori therapy, S. boulardii 500 mg twice daily reduced antibiotic-associated diarrhea versus no probiotic.
53.SupplementDEX Database: Helicobacter pylori (H. pylori) — Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study2002
In 85 H. pylori patients, probiotics including S. boulardii reduced treatment side effects, with mixed effects on eradication across strains.
54.SupplementDEX Database: Necrotising enterocolitis — Using probiotics in paediatric populations2022
A pediatric position statement noted probiotics may reduce necrotizing enterocolitis mortality in preterm infants, though strain and dosing guidance remain limited.
55.SupplementDEX Database: Necrotising enterocolitis — Use of Probiotics in Preterm Infants2021
A review cautioned that U.S. probiotic supplements lack FDA drug approval and should not be marketed to prevent NEC or sepsis in preterm infants.
56.SupplementDEX Database: Necrotising enterocolitis — AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders2020
AGA clinical practice guidelines concluded most probiotics lack sufficient evidence for GI disorders and should not be routinely recommended outside selected cases.
57.SupplementDEX Database: Necrotising enterocolitis — Probiotics and Preterm Infants: A Position Paper by the European Society for Paediatric Gastroenterology Hepatology and Nutrition Committee on Nutrition and the European Society for Paediatric Gastroenterology Hepatology and Nutrition Working Group for Probiotics and Prebiotics2020
A European position paper noted probiotics may reduce NEC and sepsis in preterm infants, but optimal strain, dose, and duration remain undefined.
58.SupplementDEX Database: Necrotising enterocolitis — Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis2017
A meta-analysis found multi-strain probiotics more effective than single-strain products for preventing NEC in very low birth weight infants.
59.SupplementDEX Database: Necrotising enterocolitis — Probiotics for prevention of necrotizing enterocolitis in preterm infants2014
A Cochrane review found probiotic prophylaxis may reduce severe NEC and sepsis in preterm infants, though strain-specific evidence varied.
SupplementDEX Database · Acne
1 reference60.SupplementDEX Database: Acne — [Treatment of acne with a yeast preparation]1989
In 139 acne patients, Perenterol yeast was effective or very good in 74.3% versus 21.7% on placebo over up to 5 months.
SupplementDEX Database · Cholera
1 reference61.SupplementDEX Database: Cholera — Saccharomyces boulardii and bismuth subsalicylate as low-cost interventions to reduce the duration and severity of cholera2015
In cholera patients, S. boulardii or bismuth subsalicylate shortened diarrhea duration versus placebo in a randomized Haiti trial.
62.SupplementDEX Database: Cognitive performance — Effect of Supplementation with Saccharomyces Boulardii on Academic Examination Performance and Related Stress in Healthy Medical Students: A Randomized, Double-Blind, Placebo-Controlled Trial2020
In medical students, 30-day S. boulardii supplementation did not significantly improve academic exam performance versus placebo.
SupplementDEX Database · Constipation
1 reference63.SupplementDEX Database: Constipation — Saccharomyces boulardii and Lactulose for Childhood Functional Constipation: A Multicenter Randomized Controlled Trial2022
In children with functional constipation, S. boulardii plus lactulose improved treatment success at 12 weeks versus monotherapy.
SupplementDEX Database · Cystic fibrosis
1 reference64.SupplementDEX Database: Cystic fibrosis — Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926)1995
In cystic fibrosis children on long-term antibiotics, S. boulardii did not significantly change intestinal Candida counts versus placebo.
65.SupplementDEX Database: Delayed onset muscle soreness — Probiotic supplementation elicits favourable changes in muscle soreness and sleep quality in rugby players2020
In elite rugby athletes, probiotic supplementation reduced muscle soreness and improved sleep quality markers versus placebo over 17 weeks.
SupplementDEX Database · Heart failure
2 references66.SupplementDEX Database: Heart failure — Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial2021
In heart failure with reduced ejection fraction, S. boulardii did not significantly improve LVEF or TMAO versus rifaximin or control.
67.SupplementDEX Database: Heart failure — Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial2015
A pilot trial in heart failure patients found S. boulardii did not significantly improve inflammatory or clinical outcomes versus placebo.
SupplementDEX Database · High cholesterol
1 reference68.SupplementDEX Database: High cholesterol — Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study2015
In hypercholesterolemic adults, S. boulardii did not significantly change total cholesterol or lipoprotein particles versus baseline in this pilot.
69.SupplementDEX Database: Irritable bowel syndrome (IBS) — Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis2021
A meta-analysis of IBS probiotic trials found multi-strain products most effective for global symptom improvement, with strain-specific effects varying by IBS subtype.
70.SupplementDEX Database: Irritable bowel syndrome (IBS) — Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii2013
In IBS-D patients, mesalazine alone or with S. boulardii improved symptoms versus baseline, with combination therapy showing the greatest benefit.
71.SupplementDEX Database: Irritable bowel syndrome (IBS) — A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life2011
In 67 IBS patients, S. boulardii 2×10^9 cells daily for 4 weeks improved quality of life and reduced diarrhea versus placebo.
SupplementDEX Database · Low birth weight
1 reference72.SupplementDEX Database: Low birth weight — A double-blinded randomized trial on growth and feeding tolerance with Saccharomyces boulardii CNCM I-745 in formula-fed preterm infants2016
In preterm neonates 30–37 weeks, S. boulardii 50 mg/kg twice daily increased weight gain (16.1 vs 10.7 g/kg/day) versus control.
SupplementDEX Database · Neonatal jaundice
2 references73.SupplementDEX Database: Neonatal jaundice — Role of Saccharomyces boulardii in Reduction of Neonatal Hyperbilirubinemia2016
In term neonates, S. boulardii reduced hyperbilirubinemia severity versus placebo when started in the first two days of life.
74.SupplementDEX Database: Neonatal jaundice — Effects of Saccharomyces boulardii on neonatal hyperbilirubinemia: a randomized controlled trial2015
In jaundiced neonates under phototherapy, S. boulardii supplementation shortened phototherapy duration and lowered bilirubin versus placebo.
SupplementDEX Database · Obesity
1 reference75.SupplementDEX Database: Obesity — Effects of 60-Day Saccharomyces boulardii and Superoxide Dismutase Supplementation on Body Composition, Hunger Sensation, Pro/Antioxidant Ratio, Inflammation and Hormonal Lipo-Metabolic Biomarkers in Obese Adults: A Double-Blind, Placebo-Controlled Trial2021
In obese adults, 60-day S. boulardii plus SOD supplementation reduced inflammation and improved body composition markers versus placebo.
SupplementDEX Database · Oral health
1 reference76.SupplementDEX Database: Oral health — Effect of a Locally Delivered Probiotic-Prebiotic Mixture as an Adjunct to Scaling and Root Planing in the Management of Chronic Periodontitis2016
As an adjunct to scaling and root planing, S. boulardii with FOS improved probing depth and clinical attachment versus SRP alone.
SupplementDEX Database · Sepsis
1 reference77.SupplementDEX Database: Sepsis — Effect and Safety of Saccharomyces boulardii for Neonatal Necrotizing Enterocolitis in Pre-term Infants: A Systematic Review and Meta-Analysis2021
A meta-analysis found S. boulardii reduced NEC stage ≥II, sepsis, and mortality in preterm infants versus placebo.
SupplementDEX Database · Pneumonia
1 reference78.SupplementDEX Database: Pneumonia — A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial2022
In mechanically ventilated trauma patients, a four-probiotic formula did not significantly reduce ventilator-associated pneumonia versus placebo.
79.SupplementDEX Database: Postoperative recovery — Randomized Clinical Trial: Impact of Oral Administration of Saccharomyces boulardii on Gene Expression of Intestinal Cytokines in Patients Undergoing Colon Resection2016
In colon surgery patients, preoperative S. boulardii reduced mucosal inflammatory cytokine expression versus conventional care.
80.SupplementDEX Database: Small intestinal bacterial overgrowth (SIBO) — Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study2023
In IBS-D with SIBO, S. boulardii plus dietary advice reduced SIBO and symptom scores more than dietary advice alone over 15 days.
81.SupplementDEX Database: Small intestinal bacterial overgrowth (SIBO) — Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis2020
In systemic sclerosis patients with SIBO, S. boulardii versus metronidazole or combination therapy reduced GI symptoms and breath-test positivity over 2 months.
SupplementDEX Database · Ulcerative colitis
1 reference82.SupplementDEX Database: Ulcerative colitis — A pilot trial of Saccharomyces boulardii in ulcerative colitis2003
In 25 ulcerative colitis patients on mesalazine, S. boulardii 250 mg three times daily for 4 weeks improved clinical and endoscopic scores versus baseline.